Marker for determination of sensitivity to anti-cancer agent
AssigneesKeio University, Kabushiki Kaisha Yakult Honsha
InventorsYusuke Tanigawara, Mitsuhiro Watanabe, Eri Arita, Akito Nishimuta, Yasuko Yamayoshi, Takeshi Matsuzaki, Shinji Sugimoto
Life of this patent
Estimating the term…
Abstract
Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved.
Claims12
A method of determining sensitivity of colorectal cancer to an anticancer agent, comprising
- (a) obtaining a biological sample from a subject having colorectal cancer;
- (b) measuring a concentration of at least one marker selected from the group consisting of L-phenylalanine and N,N-dimethyl glycine in said biological sample obtained in (a);
- (c) administering to said subject an anticancer agent selected from the group consisting of irinotecan, a salt of irinotecan, SN-38, and a salt of SN-38;
- (d) obtaining a biological sample from said subject following said administering;
- (e) measuring a concentration of at least one marker selected from the group consisting of L-phenylalanine and N,N-dimethyl glycine in said biological sample obtained in (d);
- (f) comparing the concentration of said at least one marker measured in (e) to the concentration of said at least one marker measured in (b) to determine whether said colorectal cancer is sensitive to said anticancer agent.
A method of determining whether an anticancer drug would provide a therapeutic response in a subject having colorectal cancer, comprising
- (a) obtaining a biological sample from a subject having colorectal cancer;
- (b) measuring a concentration of at least one marker selected from the group consisting of L-phenylalanine and N,N-dimethyl glycine in said biological sample obtained in (a);
- (c) administering to said subject an anticancer agent selected from the group consisting of irinotecan, a salt of irinotecan, SN-38, and a salt of SN-38;
- (d) obtaining a biological sample from said subject following said administering;
- (e) measuring a concentration of at least one marker selected from the group consisting of L-phenylalanine and N,N-dimethyl glycine in said biological sample obtained in (d);
- (f) comparing the concentration of said at least one marker measured in (e) to the concentration of said at least one marker measured in (b) to determine whether said anticancer agent would provide a therapeutic response in said subject.
Dependencies are inferred from the claim text.